Dose Response Relationship of Oxytocin on Irritability in Youths

Status Terminated

Clinical Trial Summary

The proposed study is a randomized, double-blind proof of concept (PoC) study on the neural impact of intranasal oxytocin (OXT) administration for adolescents (age 14 to 18), demonstrating a clinically significant level of irritability as defined by a score of ≥4 on the Affective Reactivity Index (ARI). Planned enrollment is 80 subjects over 3 years.

Clinical Trial Description

Endogenous oxytocin (OXT) has been a focus of prior psychiatric research due to its role in pro-social behavior, and modulation of response to social/emotional stimuli. Although many studies argue that the intranasal administration of OXT can produce behavioral as well as neural changes, there is surprisingly little comprehensive research on this issue. Most of the previous studies are limited by using a single dose of intranasal OXT in small samples, and there is no current consensus regarding appropriate dosage and very little data on neural impact as a function of dose. There has been little consideration of the relation between pharmacokinetics (peripheral level of OXT after administration) and the degree of induced neural changes. None of these issues have been studied in a pediatric population with clinically significant psychopathology. This study is proposed to determine the extent to which neural changes are induced by OXT intranasal administration, by examining the dose-response relationship (the degree of neural changes induced by various doses of OXT) and the correlation of pharmacokinetics (peripheral level of OXT after administration and the induced neural changes) in youths with clinically significant psychopathology. The form of psychopathology targeted is irritability: the increased propensity to exhibit anger relative to peers.One of the neurobiological mechanisms of irritability implicates dysfunction in the acute threat response system. OXT, with its most commonly proposed mechanism being reduction of hyperactivity in the acute threat response system, is a potentially promising agent to induce neural changes in the target brain areas of the acute threat response system for youths with high levels of irritability. The study aims to quantify the extent to which different doses of OXT will reduce the activation of the acute threat response system to emotional stimuli in youths with high levels of irritability. Both resting state and task-based functional MRI will be used , using affective-cognitive tasks with demonstrated test-retest reliability and capability of capturing the core target areas of OXT administration in the acute threat response system. Pharmacokinetics (plasma and saliva level) after OXT administration will be examined to determine correlation with the induced neural changes in the target areas. ;

Study Design

Related Conditions & MeSH terms

Irritable Mood

Clinical Trial Details

NCT number	NCT03863288
Study type	Interventional
Source	University of Nebraska
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	February 18, 2022
Completion date	February 27, 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06133231` - Optimizing Research With Diverse Families	N/A
Completed	`NCT03697837` - Digital Parent Training for Disruptive Behaviors in Children	N/A
Completed	`NCT04776304` - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms	N/A
Recruiting	`NCT01326663` - Divalproex Sodium for Mood Swings and Alcohol Use Following Head Injury.	N/A
Completed	`NCT03592368` - Hostile Interpretation Bias Training to Treat Irritability	N/A
Enrolling by invitation	`NCT04635618` - Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19	N/A
Enrolling by invitation	`NCT05043805` - Dextromethorphan Added on for Children With Chronic Irritability	Phase 4
Completed	`NCT02507284` - Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease	Phase 2
Completed	`NCT00627250` - Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability	N/A
Recruiting	`NCT05388656` - Estrogen Variability and Irritability During the Menopause Transition	Phase 4
Active, not recruiting	`NCT05260398` - Examining the Impacts on In-School Behaviors of In-Home Videogame Play	N/A
Completed	`NCT04715932` - Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)	Phase 2
Recruiting	`NCT05414708` - Art Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms	N/A
Not yet recruiting	`NCT06020261` - Parent Management Training to Treat Irritability	N/A
Recruiting	`NCT05528926` - RESist Against Irritability Superiority Trial	N/A
Completed	`NCT05974241` - Irritability in Children With ADHD and Emotion Dysregulation	Phase 4
Terminated	`NCT01675960` - Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children	Phase 2
Recruiting	`NCT05930886` - Focus Groups in Ethnically and Racially Diverse Families

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.